Dyspnea and Reversibility Profile of P2Y12 Antagonists: Systematic Review of New Antiplatelet Drugs

Conclusions The reversible P2Y12 antagonists ticagrelor, cangrelor, and elinogrel have an increased incidence of dyspnea in increasing order when compared with irreversible P2Y12 inhibitors such as clopidogrel or prasugrel.

http://link.springer.com/10.1007/s40256-014-0071-6

Source: American Journal of Cardiovascular Drugs - August 1, 2014 Category: Cardiology Source Type: research